Windlas Biotech Ltd. (WINDLAS): Windlas Biotech Share Price Rises 8.71% as Stock Enters Top Gainers Today

Windlas Biotech Ltd. rose to Rs 917.5, up 8.71% today, taking its market capitalisation to Rs 1,823.52 crore and placing it among notable small cap gainers.

Windlas Biotech Share Price moved up to Rs 917.5 on 11 August 2026, a gain of 8.71% from the previous close of Rs 844, lifting the company’s market capitalisation to Rs 1,823.52 crore. In Stock Market Today trade, the move placed the pharmaceutical company among notable Top Gainers Today and made it relevant for investors tracking Small Cap momentum, price action and Healthcare names.

The verified data confirms a strong same-day price rise, with the stock opening at Rs 840, dipping to Rs 819, and then climbing to an intraday high of Rs 925. Total traded volume stood at 2,54,638 shares, including 2,44,305 shares on NSE and 10,333 shares on BSE, while turnover was Rs 0.95 crore on the reported exchange data. That combination of a sizeable day gain and active participation explains why Windlas Biotech Stock News is drawing attention today.

The supplied data establishes what happened, but it does not establish a company-specific catalyst behind the move. Even so, Windlas Biotech Share Price Today is trending because the stock cleared the workflow’s qualifying price-rise screen for its Small Cap category, while its valuation and profitability metrics offer enough context to justify closer monitoring. For investors following Univest, the next things to watch are whether the stock sustains levels near the day high, how its valuation compares with the Pharmaceuticals & Drugs benchmark, and how it stacks up against listed peers on return ratios and market capitalisation.

Windlas Biotech Ltd. (WINDLAS) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 917.5
Previous Close	Rs 844
Today's Change	+Rs 73.5 (+8.71%)
Day Open	Rs 840
Day High	Rs 925
Day Low	Rs 819
Current Volume (BSE)	10,333
BSE Traded Volume	10,333
NSE Traded Volume	2,44,305
Combined NSE + BSE Volume	2,54,638
Turnover	Rs 0.95 crore
Market Capitalisation	Rs 1,823.52 crore
Market Cap Category	Small Cap

Windlas Biotech Ltd. (WINDLAS) traded at Rs 917.5. versus the previous close of Rs 844, a rise of 8.71%. The stock opened at Rs 840, reached Rs 925, touched Rs 819. Reported volume was 10,333.

Windlas Biotech Ltd. (WINDLAS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,823.52 crore
P/E Ratio	26.21x
P/B Ratio	3.39x
ROE	12.87%
ROCE	14.88%
EPS	Rs 32.2
Dividend Yield	0.75%

Windlas Biotech Ltd. was valued at a P/E ratio of 26.21x, a P/B ratio of 3.39x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 12.87% and ROCE of 14.88%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 32.2, dividend yield of 0.75%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Windlas Biotech Fundamental Analysis begins with scale and valuation. At the current price, the company’s market capitalisation stands at Rs 1,823.52 crore, placing it firmly in the Small Cap segment. The stock is trading at a price-to-earnings ratio of 26.21 and a price-to-book ratio of 3.39. Those numbers suggest the market is assigning a valuation premium to the company’s net worth relative to many smaller businesses, but the right comparison is not in isolation; it is against the industry benchmark and peers.

On profitability, Windlas Biotech reports return on equity of 12.87% and return on capital employed of 14.88%. These are useful measures because ROE shows the return generated on shareholder equity, while ROCE indicates how effectively the business uses overall capital. In addition, earnings per share stand at 32.2, which gives investors a direct link between the stock price and the company’s earnings base. Windlas Biotech Share Price therefore reflects about 26.21 times its trailing earnings using the supplied P/E ratio.

Book value and dividend metrics add another layer to Windlas Biotech Stock Analysis. The stock’s P/B ratio of 3.39 means the market values the shares at 3.39 times their accounting net worth. Dividend yield is 0.75, which indicates the historical payout relative to the current price level, rather than any assured future distribution. For investors reading Windlas Biotech Share Price Today, that matters because the stock is not being watched only for price movement; it also carries measurable profitability and an existing dividend profile.

Overall, the supplied fundamentals provide context rather than a verdict. A P/E of 26.21 is near the industry median rather than dramatically stretched against the benchmark data, while ROE of 12.87% and ROCE of 14.88% point to reasonable operating quality. That makes the latest share price rise noteworthy enough for Univest readers to examine beyond the headline move and into sector and peer positioning.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	26.21x
Benchmark Median P/E	25.7x
Benchmark Average P/E	69.27x
Benchmark P/E Range	3.08x to 3,396.3x
Company P/B Ratio	3.39x
Benchmark Median P/B	1.8x
Company ROE	12.87%
Benchmark Median ROE	10.59%
Company ROCE	14.88%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 1,823.52 crore
Benchmark Median Market Cap	Rs 146.99 crore

Windlas Biotech Ltd. (WINDLAS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Windlas Biotech Ltd. (WINDLAS) has a P/E ratio of 26.21x, which is above the benchmark median of 25.7x, a difference of +1.98%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Windlas Biotech Ltd. (WINDLAS) has a ROE of 12.87%, which is above the benchmark median of 10.59%, a difference of +21.53%. Windlas Biotech Ltd. (WINDLAS) has a ROCE of 14.88%, which is above the benchmark median of 12.98%, a difference of +14.64%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Windlas Biotech operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, so the most relevant lens is the supplied same-industry benchmark. Across 137 companies in this benchmark scope, the company’s P/E of 26.21 sits slightly above the median P/E of 25.7 but far below the average of 69.27. That average is likely influenced by outliers, given the full P/E range runs from 3.08 to 3,396.3 across 104 companies with available P/E data.

That context matters for Windlas Biotech Share Price because it suggests the stock is not trading at an extreme multiple relative to the broader Pharmaceuticals & Drugs pack. On price-to-book, the company’s 3.39 stands above the benchmark median of 1.8 and above the average of 2.49 across 136 companies. In other words, the market is assigning Windlas Biotech a richer book-value multiple than the industry’s central tendency.

Profitability offers a more balanced picture. Windlas Biotech’s ROE of 12.87% is above the benchmark median of 10.59% and also above the average of 8.24. Its ROCE of 14.88% is above the median of 12.98% but below the average of 15.72. This combination suggests the company’s return profile is stronger than the typical industry midpoint, although not uniformly ahead of every benchmark measure.

Scale is another important part of Windlas Biotech Market Cap analysis. The company’s market capitalisation of Rs 1,823.52 crore is well above the benchmark median of Rs 146.99 crore and also above the average of Rs 500.01 crore within the 137-company universe. The range extends from Rs 6.55 crore to Rs 3,032.97 crore, indicating Windlas sits in the upper band of its industry set by size. For Univest readers, that combination of above-median scale, near-median P/E and above-median ROE helps explain why today’s price rise is being watched closely.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	0	0.76	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.32	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	8.67	0	5.36

Windlas Biotech Ltd. (WINDLAS) has a P/E ratio of 26.21x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.87% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 14.88% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Windlas Biotech Ltd. (WINDLAS) has a market capitalisation of Rs 1,823.52 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Windlas Biotech’s peer set in the supplied Pharmaceuticals & Drugs universe shows a mixed but informative relative position. Its market capitalisation of Rs 1,823.52 crore is below peers such as Dishman Carbogen Amcis at Rs 3,032.97 crore, Hikal at Rs 2,799.54 crore, Kwality Pharmaceuticals at Rs 2,707.2 crore and Beta Drugs at Rs 2,631.45 crore. It also sits below Panacea Biotec, Sai Parenteral’s, Solara Active Pharma Sciences, NGL Fine-Chem, Venus Remedies and Hester Biosciences, all of which have supplied market caps above Rs 2,000 crore.

On valuation, Windlas Biotech’s P/E of 26.21 is lower than Kwality Pharmaceuticals at 40.09, Beta Drugs at 66.92, Sai Parenteral’s at 181.97 and NGL Fine-Chem at 44.48. At the same time, it is higher than Venus Remedies at 17.49 and Hester Biosciences at 15.63. That places Windlas in a middle valuation band among the peers for which P/E data is available, rather than at an aggressive extreme.

Its P/B ratio of 3.39 is above Hikal’s 2.32, Solara’s 1.93, Dishman Carbogen Amcis’ 0.76 and Venus Remedies’ 2.96, but below Kwality Pharmaceuticals’ 9.77, Beta Drugs’ 10.59, Panacea Biotec’s 8.67, NGL Fine-Chem’s 6.5 and Hester Biosciences’ 4.68. On returns, ROE of 12.87% is below Hikal’s 15.22%, Kwality’s 28.21%, Beta Drugs’ 18.65%, Solara’s 17.23%, NGL Fine-Chem’s 27.9% and Hester’s 16.17%, but above Dishman Carbogen Amcis’ -2.89%, Panacea Biotec’s 0 and Venus Remedies’ 9.85%.

ROCE tells a similar story. Windlas at 14.88% stands below Hikal’s 16.15%, Kwality’s 26.35%, Beta Drugs’ 22.17%, Solara’s 15.34% and NGL Fine-Chem’s 33.91%, while remaining above Dishman Carbogen Amcis’ -0.26%, Panacea Biotec’s 5.36%, Venus Remedies’ 7.89% and Hester Biosciences’ 14.12%. For Windlas Biotech Share Price, that peer picture suggests a company priced around the middle of its group with returns that are respectable, though not dominant.

Why Investors Are Watching Windlas Biotech

Windlas Biotech Share Price is being watched because today’s move combined a meaningful percentage gain with a strong recovery from the session low and a close near the day’s upper range. In Market News terms, that puts the stock on the radar of investors scanning momentum names, but the follow-through questions are more analytical: how expensive is it versus the industry, are return ratios supportive, and where does it sit within the listed pharma peer set?

• Verified price action: the stock rose 8.71% to Rs 917.5 from Rs 844, after trading between Rs 819 and Rs 925.
• Volume context: total traded volume reached 2,54,638 shares across NSE and BSE, with 2,44,305 shares on NSE.
• Fundamental context: market capitalisation is Rs 1,823.52 crore, P/E is 26.21, P/B is 3.39, ROE is 12.87% and ROCE is 14.88%.
• Sector positioning: P/E is close to the industry median, while ROE and ROCE are above the benchmark medians.
• Peer positioning: valuation sits between lower-multiple and higher-multiple peers, rather than at the extremes.

What investors may monitor next is whether Windlas Biotech Share Price can hold near levels reached in today’s rally, and whether future market attention continues to be supported by relative profitability and sector valuation context. Univest readers may also keep an eye on how the stock’s premium to industry book value evolves as the market reassesses the name.

About Windlas Biotech

Windlas Biotech Ltd. is part of India’s Healthcare sector and operates within the Pharmaceuticals & Drugs industry. That places the company in a segment where investors often compare listed players through valuation multiples such as P/E and P/B, alongside profitability measures including ROE and ROCE. In today’s Windlas Biotech Company News, that industry identity is central because the stock is not moving in a vacuum; it is being judged against a 137-company same-industry benchmark.

The supplied data does not provide a longer business description, product mix or segment-level revenue split, so the most reliable company context comes from its market positioning within this industry set. With a market capitalisation of Rs 1,823.52 crore, Windlas is much larger than the benchmark median company at Rs 146.99 crore and also above the benchmark average of Rs 500.01 crore. That means it sits in the upper size band of the listed Pharmaceuticals & Drugs universe covered here.

For investors tracking Windlas Biotech Share News and Windlas Biotech Latest News, this combination matters. The company is a listed pharma stock with an established earnings base, reflected in EPS of 32.2, a P/E of 26.21 and return ratios that are above the benchmark medians. In practical terms, Windlas Biotech is being watched today as a sizable small cap healthcare company whose market move is backed by enough disclosed valuation and profitability data to support closer stock analysis on Univest.

Track Windlas Biotech Share Price on Univest

Use Windlas Biotech Ltd. (WINDLAS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Windlas Biotech Share Price can use Univest to monitor live share price moves, market-cap changes, valuation ratios and broader stock performance in one place. Windlas Biotech Share Price Today is only one part of the picture; users also track P/E, P/B, ROE, ROCE, EPS, dividend yield, 52-week levels and sector positioning as the data updates.

Univest also helps users compare Windlas Biotech Stock News with peer metrics across the Pharmaceuticals & Drugs space, making it easier to see whether a price rise is isolated or part of a wider industry pattern. For readers interested in Windlas Biotech Fundamental Analysis, the platform offers a structured view of market data, return ratios and company context without turning a market update into a recommendation.

Frequently Asked Questions

Why is Windlas Biotech Share Price rising today?

Ans. Windlas Biotech Share Price rose because the stock recorded an 8.71% same-day gain to Rs 917.5 from Rs 844. The supplied data confirms the price event and active trading volume, but it does not establish a company-specific catalyst.

What is Windlas Biotech Share Price Today?

Ans. Windlas Biotech Share Price Today is Rs 917.5. That is Rs 73.5 above the previous close of Rs 844, representing an 8.71% gain, and it places the stock among notable small cap gainers in today’s session.

What were the day high and day low for Windlas Biotech shares?

Ans. Windlas Biotech traded between a day low of Rs 819 and a day high of Rs 925. The stock opened at Rs 840 and later climbed close to the top of that range, highlighting strong intraday recovery.

What is the market capitalisation of Windlas Biotech?

Ans. Windlas Biotech has a market capitalisation of Rs 1,823.52 crore. That places it in the Small Cap category and above the Pharmaceuticals & Drugs benchmark median market capitalisation of Rs 146.99 crore in the supplied dataset.

How much volume was traded in Windlas Biotech today?

Ans. Total traded volume in Windlas Biotech stood at 2,54,638 shares today. Of this, 2,44,305 shares were traded on NSE and 10,333 shares on BSE, while reported turnover on the supplied exchange data was Rs 0.95 crore.

Is Windlas Biotech expensive compared with its industry benchmark?

Ans. Windlas Biotech’s P/E ratio is 26.21, slightly above the industry median of 25.7 but well below the average of 69.27. Its P/B ratio of 3.39 is higher than both the benchmark median of 1.8 and average of 2.49.

How profitable is Windlas Biotech based on the supplied data?

Ans. Windlas Biotech reports ROE of 12.87% and ROCE of 14.88%. Those figures are above the benchmark medians of 10.59% and 12.98%, showing returns that are better than the industry midpoint in the supplied comparison.

What are the EPS and dividend yield of Windlas Biotech?

Ans. Windlas Biotech has an EPS of 32.2 and a dividend yield of 0.75. EPS reflects earnings attributable to each share, while dividend yield shows the historical payout relative to the current market price.

How does Windlas Biotech compare with listed pharma peers?

Ans. Windlas Biotech’s P/E of 26.21 is below peers such as Kwality Pharmaceuticals, Beta Drugs and NGL Fine-Chem, but above Venus Remedies and Hester Biosciences. Its return ratios are respectable, though not the strongest in the peer set.

What should investors track next in Windlas Biotech Stock News?

Ans. Investors may track whether Windlas Biotech holds near today’s high zone after rising to Rs 917.5. Valuation versus the Pharmaceuticals & Drugs benchmark, peer return ratios and ongoing volume participation are also important factors to monitor.